Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Long-Term Outcomes in Head and Neck Paragangliomas Managed with Intensity-Modulated Radiotherapy.

Author information

Affiliations

  • 1. Sorbonne Universités, Department of Radiation Therapy and Oncology, Hôpital Pitié-Salpêtrière Charles Foix, APHP, Paris, France.
      Authors
    • Rougier G 1
    • Rochand A 1
    • Bourdais R 1
    • Meillan N 1
    • Riet F 1
    • Mazeron JJ 1
    • Jacob J 1
    • Simon JM 1
    • Maingon P 1
    • Feuvret L 1
    (10 authors)
  • 2. Sorbonne Universités, Department of ENT, Head and Neck Surgery, Hôpital Pitié-Salpêtrière Charles Foix, APHP, Paris, France.
      Authors
    • Tankere F 2
    (1 author)
  • 3. Department of ENT, Head and Neck Surgery, Hôpital Lariboisière, APHP, Paris, France.
      Authors
    • Herman P 3, 4
    (1 author)
  • 4. Université de Paris, Paris, France.
      Authors
    • Herman P 3, 4
    • Burnichon N 4
    (2 authors)
  • 5. Sorbonne Universités, Department of Nuclear Medicine, Hôpital Pitié-Salpêtrière Charles Foix, APHP, Paris, France.
      Authors
    • Lussey-Lepoutre C 5
    (1 author)

ORCIDs linked to this article

The Laryngoscope, 31 May 2022, 133(3):607-614
https://doi.org/10.1002/lary.30226 PMID: 35638238 

Abstract 

Objectives

Head & Neck Paragangliomas have been historically relying on surgery mostly, with worsened quality of life and major sequelae. Conventional external radiation therapy seems to offer an equivalent control rate with a low toxicity profile. The aim of this study was to assess the safety and efficiency of intensity-modulated radiation therapy in Head & Neck paragangliomas.

Methods

This is a retrospective monocentric study conducted in a referral center, including all patients treated with IMRT, whether as an exclusive or post-operative treatment for a tympanic and jugular, carotid, or vagal paraganglioma. Data collection was performed through the manuscript and computerized medical files, including consultation, operative, imaging, pathological analyses, delineation, and treatment planning reports. Success was defined as the complete or partial regression or stabilization without progression, or relapse in accordance with the RECIST criteria. Acute toxicities and long-term sequelae were assessed.

Results

Our cohort included 39 patients included between 2011 and 2021: 18 patients treated for a TJ PG (45.9%), 11 patients for a carotid PG (28.4%), and 9 for a vagal PG (23.1%). Twenty-nine patients had IMRT as an exclusive treatment (74.4%), whereas 10 patients had a post-operative complementary treatment (25.6%). Median follow-up in our cohort was 2318 days (average = 2200 days, 237-5690, sd = 1281.9). Among 39 patients, 37 were successfully controlled with IMRT (94.8%), and the toxicity profile was low without any major toxicity.

Conclusion

IMRT seems an ideal treatment, whether exclusive or post-operative for Head & Neck paragangliomas.

Level of evidence

3 Laryngoscope, 133:607-614, 2023.

Full text links 

Read article at publisher's site: https://doi.org/10.1002/lary.30226

Citations & impact 

Impact metrics

2
Citations
Jump to Citations

Article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.